Our findings, for the first time, propose that targeting SMAD4 as a pivotal transducer of the TGF-β-signaling pathway may be effective as a supplementary targeted therapy against renal CSCs and may improve the RCC prognosis, particularly the ccRCC subtype. This evidence concerns the gene TGFB1 and renal cell carcinoma.